September 12, 2023
Press Releases
July 5, 2023
Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series
June 29, 2023
Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)
May 24, 2023
Panavance Therapeutics to Present at the Biotechnology Innovation Organization (BIO) International Convention
April 17, 2023
Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer
April 12, 2023
Panavance Therapeutics to Present at the BioNJ Annual BioPartnering Conference
March 20, 2023
Panavance Therapeutics Announces Acceptance of Abstract to be Presented at
the American Association for Cancer Research (AACR) Annual Meeting 2023
January 5, 2023
Panavance Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
December 5, 2022
Panavance Therapeutics to Participate at the Virtual Investor Innovations in Oncology Spotlight Event
November 14, 2022